New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Amgen Inc.

AMGN

Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.

Revenue
+8.45%
EPS
+19.4%
Free cash flow
−14.0%
Total debt
−1.06%

Quarter to September 2026, against a year earlier

439.26 0.46 +0.10%
Market cap
$237.4B
P/E
25.2×
Fwd P/E FY26e
24.0×
Dividend yield
2.84%
F-score
7/9
ROIC
14.3%
Net debt / EBITDA
2.9×
Payout ratio
0.7×

Amgen Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 6:37 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 35 added · 31 removed · 48 modified; 14 with only figures updated; 8 moved without change